Compare Airbnb, Inc. (ABNB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Airbnb, Inc. vs Novo Nordisk A/S — how do they compare? Airbnb, Inc. trades at $142.83 (market cap $88.31B), while Novo Nordisk A/S trades at $48.85 (market cap $220.20B). The key difference: Novo Nordisk A/S is far larger — about 2.5× Airbnb, Inc.'s market cap, and Novo Nordisk A/S pays a 3.63% dividend while Airbnb, Inc. pays none. Which is the better fit depends on your goals.
| ABNB | NVO | |
|---|---|---|
Market Cap | $88.31B | $220.20B |
Sector | Consumer Cyclical | Health |
52-Week High | $148.93 | $71.70 |
52-Week Low | $111.54 | $35.29 |
Enterprise Value | $78.84B | $239.16B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) trades at $148.80, showing minimal daily movement with a slight decline of 0.09%. The stock maintains a bullish technical outlook with strong moving average signals and trades near pivot point resistance at $149. Fundamentally, the company demonstrates robust profitability with 82.9% gross margins and 19.9% net income margin, though recent quarters have seen earnings misses against expectations. Revenue growth continues with 2025 reaching $12.24 billion, supported by the company's asset-light model and global travel recovery.
The investment case balances strong fundamentals against valuation concerns, with a P/E of 36.5 suggesting premium pricing. Analyst consensus remains positive with a $161.80 price target, though recent earnings misses and CEO stock sales warrant monitoring. Key risks include travel demand sensitivity, competitive pressures, and execution of new initiatives like hotel expansion and AI development. The stock offers growth exposure to travel recovery but requires careful valuation assessment.
Novo Nordisk (NVO) trades at $49.64, down 1.57% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with $309.1B revenue in 2025 and impressive profitability metrics including 37.2% net income margin and 71.4% ROE. Recent earnings beats and Medicare's GLP-1 coverage expansion for weight-loss drugs provide positive catalysts. Analyst consensus remains strongly bullish with 22 buy ratings versus only 3 sell recommendations.
NVO presents a compelling investment case with strong earnings growth, market leadership in GLP-1 therapies, and favorable valuation at 11.82 P/E. Key risks include intensifying competition in obesity drugs and potential pricing pressures. The stock's current technical setup near support at $49 suggests potential for rebound, supported by institutional confidence and positive business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
